Centessa Pharmaceuticals plc Logo

Centessa Pharmaceuticals plc

Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.

CNTA | NDAQ

Overview

Corporate Details

ISIN(s):
US1523091007
LEI:
Country:
United States of America
Address:
3RD FLOOR, ALTRINCHAM, CHESHIRE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering and developing transformational medicines for patients with unmet medical needs. The company leverages a data-driven Research & Development model to advance a portfolio of innovative assets. Its lead program is a potential best-in-class orexin receptor 2 (OX2R) agonist being developed for the treatment of sleep-wake disorders. The company's pipeline also includes programs targeting other conditions, such as hemophilia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Centessa Pharmaceuticals plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Centessa Pharmaceuticals plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Centessa Pharmaceuticals plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America CYCN
Cyfuse Biomedical K.K. Logo Japan 4892
CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America CYTK
CytoMed Therapeutics Ltd Logo
Develops off-the-shelf cell immunotherapies using γδ T cells & NK cells for cancer treatment.
United States of America GDTC
CytomX Therapeutics, Inc. Logo
Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.
United States of America CTMX
Daebonglsco.,Ltd Logo
Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.
South Korea 078140
DaehanPharmaceutical Logo
Develops and manufactures pharmaceuticals and health foods for human and animal markets worldwide.
South Korea 023910

Talk to a Data Expert

Have a question? We'll get back to you promptly.